Iodide

Iodide

SCHEMBL1219508

CCCCCCCCCCCn1cc[n+](C)c1.[I-]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.93
HSP90AA1 P07900 2/20 0.93
KMT2A Q03164 2/20 0.93
SMN1; SMN2 Q16637 2/20 0.93
APAF1 O14727 1/20 0.93
NPC1 O15118 1/20 0.93
PLA2G1B P04054 1/20 0.93
MAPT P10636 1/20 0.93
MAPK1 P28482 1/20 0.93
HTT P42858 1/20 0.93
RAB9A P51151 1/20 0.93
NPSR1 Q6W5P4 1/20 0.93
ATG4B Q9Y4P1 1/20 0.93
FDPS P14324 16/20 0.43
TBXAS1 P24557 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL594561 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL5087098 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL5091915 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL926313 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL5085005 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL1758281 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL2125637 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL1735056 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Iodide SCHEMBL5088502 1.00 MEN1 (0.93) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Hydrochloric Acid SCHEMBL29429158 0.98 MEN1 (0.89) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255195-B2 Ionic liquids, functionalized particulates, and fluoropolymer composites THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2016-02-09 US disclosed
US-20140045977-A1 NOVEL IONIC LIQUIDS, FUNCTIONALIZED PARTICULATES, AND FLUOROPOLYMER COMPOSITES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-02-13 US disclosed
US-8563657-B2 Ionic liquids, functionalized particulates, and fluoropolymer composites THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2013-10-22 US disclosed
US-20110033647-A1 NOVEL IONIC LIQUIDS, FUNCTIONALIZED PARTICULATES, AND FLUOROPOLYMER COMPOSITES THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2011-02-10 US disclosed
US-20080214386-A1 Stability; easily separated from solution; surface treatment of catalyst with Group seven compound; reacting epoxide with carbon dioxide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033647-A1 NOVEL IONIC LIQUIDS, FUNCTIONALIZED PARTICULATES, AND FLUOROPOLYMER COMPOSITES FLNA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 MEN1 2568/4885HSP90AA1 3946/4885KMT2A 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.